Filing Details

Accession Number:
0000899243-21-034025
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-24 16:06:10
Reporting Period:
2021-08-18
Accepted Time:
2021-08-24 16:06:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1789972 Cullinan Oncology Inc. CGEM Biological Products, (No Disgnostic Substances) (2836) 813867811
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1838061 Jennifer Michaelson C/O Cullinan Oncology, Inc.
One Main Street, Suite 520
Cambridge MA 02142
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-18 4,000 $4.30 26,911 No 4 M Direct
Common Stock Disposition 2021-08-18 2,863 $27.50 24,048 No 4 S Direct
Common Stock Disposition 2021-08-18 1,137 $28.07 22,911 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-08-18 4,000 $0.00 4,000 $4.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
225,978 2030-10-28 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  3. 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.